Integrin β3 was activated by transforming growth factor-β1 (TGF-β1) to increase the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance, then EMT and anoikis resistance was observed in lung cancer cell lines [27]. The gene discussed is EGFR; the disease is lung carcinoma.